IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
Total raised: $9.46M
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.02.2024 | - | $9.46M | - |
Mentions in press and media 6
| Date | Title | Description |
| 21.02.2024 | IsomAb: A Beacon of Hope for Diabetic Peripheral Arterial Disease | IsomAb, a biopharmaceutical company based in Nottingham, UK, has secured a significant £7.5 million in funding to advance its groundbreaking treatment for diabetic peripheral arterial disease (PAD). Led by CEO Jackie Turnbull, IsomAb focuse... |
| 20.02.2024 | IsomAb Raises £7.5M in Funding | IsomAb CEO Jackie Turnbull IsomAb, a Nottingham, UK-based biopharmaceutical company, raised £7.5M in funding. The round was led by Broadview Ventures with participation from MEIF Proof of Concept & Early Stage Fund, which is managed by ... |
| 20.02.2024 | IsomAb secures £7.5M for treatment of diabetic peripheral arterial disease | Today IsomAb — a University of Nottingham spin-out pioneering a new treatment for people with diabetes at risk of amputation — has raised £7.5 million in funding. The company focuses on treating peripheral arterial disease (PAD). In this re... |
| 14.09.2023 | SCVC's new fund to propel Pre-Seed and Seed stage tech innovation | Early-stage deep tech investor SCVC, has announced the first close of its second fund, with a target of up to $100 million. The Bristol-based firm invests in advanced technologies to improve the health of people and the planet - from biotec... |
| - | IsomAb | “Home | IsomAb ” |
| - | IsomAb Closes £7.5 Million To Develop Isoform-Specific Disease Modifying Antibody Treatment | IsomAb Ltd – a UK-based biotechnology company – announced today the closing of a £7.5 million (approximately US$9.4 million) Seed financing round, led by Broadview Ventures, with further backing from existing investor, SCVC and participatio... |